Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Weight Loss | 24 | 2024 | 410 | 6.950 |
Why?
|
| Obesity | 28 | 2024 | 1111 | 5.160 |
Why?
|
| Caloric Restriction | 11 | 2024 | 92 | 3.680 |
Why?
|
| Body Composition | 15 | 2019 | 327 | 3.060 |
Why?
|
| Exercise | 12 | 2023 | 605 | 2.640 |
Why?
|
| Bone Density | 9 | 2024 | 169 | 2.460 |
Why?
|
| Diet, Reducing | 8 | 2020 | 85 | 2.380 |
Why?
|
| Inflammation | 10 | 2013 | 507 | 2.220 |
Why?
|
| Overweight | 8 | 2016 | 252 | 1.800 |
Why?
|
| Dietary Proteins | 4 | 2019 | 63 | 1.630 |
Why?
|
| Bone Density Conservation Agents | 2 | 2024 | 23 | 1.540 |
Why?
|
| Aged | 41 | 2024 | 10249 | 1.520 |
Why?
|
| Resistance Training | 3 | 2024 | 58 | 1.440 |
Why?
|
| Physical Fitness | 4 | 2013 | 120 | 1.370 |
Why?
|
| Aging | 9 | 2017 | 942 | 1.320 |
Why?
|
| Adipose Tissue | 4 | 2020 | 320 | 1.250 |
Why?
|
| Female | 49 | 2024 | 19943 | 1.230 |
Why?
|
| Bone and Bones | 3 | 2023 | 91 | 1.140 |
Why?
|
| Adiposity | 4 | 2020 | 190 | 1.100 |
Why?
|
| Humans | 56 | 2024 | 32271 | 1.070 |
Why?
|
| Male | 39 | 2024 | 19437 | 1.070 |
Why?
|
| Interleukin-6 | 6 | 2023 | 224 | 1.060 |
Why?
|
| Body Mass Index | 12 | 2023 | 863 | 1.040 |
Why?
|
| Weight Gain | 4 | 2017 | 104 | 1.000 |
Why?
|
| Gait | 2 | 2020 | 120 | 0.970 |
Why?
|
| Postmenopause | 7 | 2017 | 424 | 0.950 |
Why?
|
| Soy Milk | 3 | 2010 | 3 | 0.950 |
Why?
|
| Fractures, Bone | 4 | 2020 | 142 | 0.900 |
Why?
|
| Alendronate | 1 | 2024 | 10 | 0.860 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 1159 | 0.860 |
Why?
|
| Middle Aged | 28 | 2024 | 11838 | 0.860 |
Why?
|
| Soybean Proteins | 4 | 2015 | 101 | 0.840 |
Why?
|
| Motor Activity | 4 | 2014 | 332 | 0.840 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 72 | 0.820 |
Why?
|
| Gastrectomy | 2 | 2021 | 70 | 0.800 |
Why?
|
| Absorptiometry, Photon | 6 | 2024 | 98 | 0.770 |
Why?
|
| Muscle, Skeletal | 6 | 2023 | 520 | 0.730 |
Why?
|
| Milk | 3 | 2010 | 13 | 0.710 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 96 | 0.680 |
Why?
|
| Uric Acid | 2 | 2013 | 26 | 0.670 |
Why?
|
| Mortality | 2 | 2019 | 122 | 0.660 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 28 | 0.640 |
Why?
|
| Continental Population Groups | 1 | 2020 | 228 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 1437 | 0.580 |
Why?
|
| Oxidative Stress | 2 | 2010 | 255 | 0.550 |
Why?
|
| Abdominal Fat | 2 | 2015 | 39 | 0.520 |
Why?
|
| Walking | 5 | 2020 | 199 | 0.510 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 49 | 0.480 |
Why?
|
| Cognition | 2 | 2016 | 547 | 0.450 |
Why?
|
| Life Style | 3 | 2014 | 394 | 0.450 |
Why?
|
| Muscle Strength | 2 | 2018 | 135 | 0.440 |
Why?
|
| Isoflavones | 3 | 2010 | 103 | 0.430 |
Why?
|
| Blood Pressure | 3 | 2015 | 864 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 534 | 0.420 |
Why?
|
| Cytokines | 3 | 2011 | 237 | 0.420 |
Why?
|
| Adiponectin | 2 | 2013 | 94 | 0.410 |
Why?
|
| Diet | 3 | 2011 | 383 | 0.410 |
Why?
|
| Prediabetic State | 1 | 2014 | 76 | 0.400 |
Why?
|
| Pilot Projects | 4 | 2021 | 554 | 0.380 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 2238 | 0.380 |
Why?
|
| Soy Foods | 2 | 2010 | 8 | 0.380 |
Why?
|
| Single-Blind Method | 6 | 2015 | 192 | 0.380 |
Why?
|
| Cause of Death | 1 | 2013 | 236 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 545 | 0.370 |
Why?
|
| Nonprescription Drugs | 2 | 2009 | 18 | 0.370 |
Why?
|
| Insulin Resistance | 2 | 2014 | 458 | 0.370 |
Why?
|
| Coronary Disease | 1 | 2013 | 226 | 0.360 |
Why?
|
| Age Factors | 5 | 2020 | 1178 | 0.360 |
Why?
|
| Corn Oil | 2 | 2009 | 4 | 0.350 |
Why?
|
| North Carolina | 4 | 2019 | 1300 | 0.350 |
Why?
|
| Risk Factors | 8 | 2017 | 3933 | 0.340 |
Why?
|
| Sarcopenia | 3 | 2017 | 50 | 0.340 |
Why?
|
| Dietary Supplements | 3 | 2012 | 188 | 0.330 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 4 | 0.330 |
Why?
|
| Interleukins | 1 | 2010 | 17 | 0.330 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 43 | 0.330 |
Why?
|
| Exercise Therapy | 1 | 2013 | 249 | 0.320 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 764 | 0.320 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 117 | 0.310 |
Why?
|
| Enzymes | 1 | 2009 | 6 | 0.300 |
Why?
|
| Plant Preparations | 1 | 2009 | 27 | 0.300 |
Why?
|
| Fish Oils | 1 | 2009 | 38 | 0.300 |
Why?
|
| Soybeans | 1 | 2009 | 42 | 0.300 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 25 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 904 | 0.290 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 38 | 0.290 |
Why?
|
| Renal Dialysis | 2 | 2009 | 275 | 0.290 |
Why?
|
| Lipids | 1 | 2010 | 253 | 0.290 |
Why?
|
| Double-Blind Method | 3 | 2021 | 566 | 0.290 |
Why?
|
| Muscular Atrophy | 1 | 2009 | 74 | 0.280 |
Why?
|
| Lumbar Vertebrae | 3 | 2019 | 93 | 0.280 |
Why?
|
| Time Factors | 4 | 2017 | 2203 | 0.280 |
Why?
|
| Hyperhomocysteinemia | 1 | 2008 | 5 | 0.280 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 3893 | 0.270 |
Why?
|
| Homocysteine | 1 | 2008 | 16 | 0.270 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 33 | 0.270 |
Why?
|
| Docosahexaenoic Acids | 1 | 2008 | 25 | 0.270 |
Why?
|
| Osteoporosis | 3 | 2024 | 51 | 0.260 |
Why?
|
| Energy Intake | 2 | 2019 | 122 | 0.250 |
Why?
|
| Health Status | 3 | 2016 | 356 | 0.250 |
Why?
|
| Prospective Studies | 5 | 2015 | 2315 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2020 | 3408 | 0.230 |
Why?
|
| Survival Analysis | 2 | 2017 | 476 | 0.210 |
Why?
|
| Research Design | 1 | 2024 | 316 | 0.190 |
Why?
|
| Prevalence | 3 | 2017 | 955 | 0.180 |
Why?
|
| Prognosis | 2 | 2017 | 1529 | 0.170 |
Why?
|
| Self-Help Devices | 1 | 2020 | 6 | 0.160 |
Why?
|
| Accidents, Home | 1 | 2020 | 10 | 0.160 |
Why?
|
| Carbohydrate Metabolism | 1 | 2020 | 21 | 0.160 |
Why?
|
| Environment Design | 1 | 2020 | 15 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 35 | 0.160 |
Why?
|
| Femur Neck | 2 | 2017 | 18 | 0.160 |
Why?
|
| Amino Acids | 1 | 2020 | 52 | 0.160 |
Why?
|
| Metabolomics | 1 | 2020 | 63 | 0.160 |
Why?
|
| Glutathione Peroxidase | 2 | 2010 | 10 | 0.160 |
Why?
|
| Disability Evaluation | 3 | 2020 | 241 | 0.160 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 41 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 2 | 2010 | 51 | 0.150 |
Why?
|
| United States | 3 | 2016 | 4069 | 0.150 |
Why?
|
| Animals | 5 | 2017 | 8196 | 0.150 |
Why?
|
| Exercise Test | 2 | 2019 | 218 | 0.150 |
Why?
|
| Hip | 1 | 2019 | 13 | 0.150 |
Why?
|
| Femur | 1 | 2019 | 73 | 0.140 |
Why?
|
| Compressive Strength | 1 | 2018 | 20 | 0.140 |
Why?
|
| Clothing | 1 | 2018 | 5 | 0.140 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 20 | 0.130 |
Why?
|
| Oxygen Consumption | 3 | 2019 | 141 | 0.130 |
Why?
|
| Hand Strength | 2 | 2015 | 98 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2017 | 1423 | 0.130 |
Why?
|
| Muscle Denervation | 1 | 2017 | 29 | 0.130 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2017 | 26 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2017 | 26 | 0.130 |
Why?
|
| Behavior Therapy | 2 | 2016 | 103 | 0.120 |
Why?
|
| Thigh | 1 | 2016 | 35 | 0.120 |
Why?
|
| Troponin T | 1 | 2017 | 92 | 0.120 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 335 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2014 | 471 | 0.120 |
Why?
|
| Women | 1 | 2015 | 12 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2020 | 818 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 327 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2016 | 1839 | 0.110 |
Why?
|
| Wrist Injuries | 1 | 2015 | 41 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3609 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 38 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 305 | 0.100 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 42 | 0.100 |
Why?
|
| Heart Function Tests | 1 | 2013 | 8 | 0.100 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2013 | 18 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 286 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 9 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Movement Disorders | 1 | 2013 | 25 | 0.100 |
Why?
|
| Community Health Centers | 1 | 2013 | 12 | 0.100 |
Why?
|
| Muscle Development | 1 | 2013 | 52 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 227 | 0.100 |
Why?
|
| Leptin | 1 | 2013 | 61 | 0.100 |
Why?
|
| Triglycerides | 2 | 2012 | 235 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 23 | 0.100 |
Why?
|
| Body Weight | 1 | 2015 | 323 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 551 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 591 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 759 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 77 | 0.090 |
Why?
|
| Dairy Products | 1 | 2012 | 13 | 0.090 |
Why?
|
| Independent Living | 1 | 2013 | 90 | 0.090 |
Why?
|
| Health Education | 1 | 2013 | 149 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 656 | 0.090 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 3 | 0.090 |
Why?
|
| Health Behavior | 1 | 2013 | 213 | 0.090 |
Why?
|
| Food, Formulated | 1 | 2011 | 13 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2013 | 208 | 0.080 |
Why?
|
| Adult | 4 | 2014 | 9260 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2011 | 46 | 0.080 |
Why?
|
| Fibrinogen | 1 | 2011 | 65 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 62 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 116 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2010 | 82 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 92 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 99 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 408 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 155 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 215 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 242 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 175 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 413 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2009 | 195 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 163 | 0.070 |
Why?
|
| Texas | 1 | 2008 | 41 | 0.070 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 250 | 0.070 |
Why?
|
| Nutrition Surveys | 1 | 2009 | 144 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 455 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 193 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1480 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 556 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2018 | 171 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2019 | 484 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1242 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2014 | 153 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 246 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 230 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 80 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 119 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2018 | 85 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2017 | 8 | 0.030 |
Why?
|
| Causality | 1 | 2017 | 37 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 95 | 0.030 |
Why?
|
| California | 1 | 2017 | 61 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 309 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 2017 | 70 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 221 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 212 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 124 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2017 | 175 | 0.030 |
Why?
|
| Spine | 1 | 2015 | 32 | 0.030 |
Why?
|
| Publication Bias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 563 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 24 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 772 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 478 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 756 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 194 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 216 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 880 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 204 | 0.020 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 2 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 8 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2012 | 15 | 0.020 |
Why?
|
| Running | 1 | 2012 | 20 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 181 | 0.020 |
Why?
|
| Calpain | 1 | 2012 | 14 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 76 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 170 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2012 | 63 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 186 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2011 | 5 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2571 | 0.020 |
Why?
|
| Insulin | 1 | 2012 | 359 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 108 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 499 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 650 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 206 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 212 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 364 | 0.020 |
Why?
|